Academic researchers in Massachusetts believe the standard BCG (bacillus Calmette-Guérin) vaccine could have a remarkable second use: a treatment to reverse advanced type 1 diabetes.
While a beta cell replacement therapy is the dream of all type 1 patients, new medical devices are hitting the market, and promise more peace of mind. However US patients could find access to t
Novo Nordisk hopes that new data supporting the cardiovascular and glycaemic safety of its Tresiba long-acting insulin will prove a game-changer in the US.
This year's American Diabetes Association conference takes place right next to San Diego's baseball stadium - and like the city's well-known Padres team, Merck and Pfizer are hoping to cove
Sanofi and Regeneron have had a tough time of late with their PCSK9-class cholesterol drug, Praluent (alirocumab), as Amgen is attempting to get Praluent removed from the US market in an on
Japan’s Taisho Pharmaceutical looks like it could be heading into private ownership, thanks to a management buyout offer (MBO) that could value the company at almost $5 bi
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio